Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2006-07-24
2010-12-14
Krass, Frederick (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S211090, C514S649000, C514S277000
Reexamination Certificate
active
07851431
ABSTRACT:
The present invention relates to methods and compositions for the treatment and/or prevention of actinic keratoses comprising a calcium channel blocking compound.
REFERENCES:
patent: 6031005 (2000-02-01), Easterling
patent: 6353028 (2002-03-01), Easterling
patent: 6525100 (2003-02-01), Easterling et al.
patent: 2002/0022664 (2002-02-01), Easterling
patent: 2004/0170675 (2004-09-01), Easterling
patent: 2004/0171684 (2004-09-01), Easterling
patent: 2004/0248099 (2004-12-01), Goppelt et al.
patent: WO 02/053171 (2002-07-01), None
Mauro et al., Keratinocyte K+ Channels Mediate Ca2+-Induced Differentiation, 1997, The Society for Investigative Dermatology, Inc., 108 (6), 864-870.
“Topical diclofenac: new preparation. Moderate efficacy in actinic keratosis,”Prescrire Int., 13:138-139, 2004.
Fitscha et al., “The Diminished Extracellular Matrix Production Induced by Isradipine, a Calcium Channel Blocker, is Completely Abolished by Cyclooxygenase Inhibition,”Prost. Leukot. Essent. Fatty Acids, 45:289-291, 1992.
Jeffes and Tang, “Actinic keratosis. Current treatment options,”Am. J. Clin. Dermatol., 1:167-179, 2000.
Jorizzo et al., “Treatment Options in the Management of Actinic Keratosis,”Cutis, 6(Suppl.):9-7, 2004.
Lober and Fenske, “Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma),”Am. J. Clin. Dermatol., 5:395-401, 2004.
Rodler et al., “Ca(2+)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells,”J. Mol. Cell Cardiol., 27:2295-2302, 1995.
Roth et al., “Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix,”Proc. Natl. Acad Sci. USA, 93: 5478-5482, 1996.
Stetler-Stevenson, “Dynamics of Matrix Turnover Durin Pathologic Remodeling of the Extracellular Matrix,”Amer. J. Pathol., 148:1345-1350 ,1996.
Bordovsky Michael J.
Easterling W. Jerry
Fulbright & Jaworski L.L.P.
Huang Gigi
Krass Frederick
Prescription Dispensing Laboratories
LandOfFree
Treatment of actinic keratoses with calcium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of actinic keratoses with calcium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of actinic keratoses with calcium channel blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217871